Form 4: Bolt Biotherapeutics Director Acquires Stock Options

Sentiment:

SEC Form 4 Filing


Director Mahendra Shah acquired 22,000 stock options in Bolt Biotherapeutics on June 12, 2024.

Summary

  • Mahendra Shah, a director of Bolt Biotherapeutics, acquired 22,000 stock options on June 12, 2024.
  • The exercise price of the options is $0.7682.
  • The options vest on the earlier of June 12, 2025, or the day before the next annual meeting of stockholders, contingent upon continuous service.
  • The options will fully vest upon a change in control of the Issuer.
  • The expiration date for the options is June 11, 2034.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing related to stock option grants.

Positives

  • The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders.

Stakeholder Impact

  • The acquisition of stock options by a director may signal confidence to shareholders.

Key Dates

DateDescription
06/12/2024Date of stock option acquisition.
06/12/2025Earliest vesting date for the stock options, contingent upon continuous service.
06/11/2034Expiration date of the stock options.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.